載入...
Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
Sorafenib and lenvatinib are the only multikinase inhibitors (MKIs) approved for the treatment of radioactive iodine refractory differentiated thyroid cancer (RR-DTC). Although they have been demonstrated to improve progression free survival and overall response rate, the risk of toxicities is very...
Na minha lista:
| 發表在: | J Pers Med |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8306329/ https://ncbi.nlm.nih.gov/pubmed/34357141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11070674 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|